Cargando…

Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

Theranostics is the highly targeted molecular imaging and therapy of tumors. Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers. Metastatic, well-differentiated gastroenteropancreatic neuroend...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grey, Neil, Silosky, Michael, Lieu, Christopher H, Chin, Bennett B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099199/ https://www.ncbi.nlm.nih.gov/pubmed/35633909 http://dx.doi.org/10.3748/wjg.v28.i17.1768

Ejemplares similares

Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects
por: Lu, Ren-Cai, et al.
Publicado: (2019)

Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms
por: Stankiewicz, Rafał, et al.
Publicado: (2022)

Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms
por: Iabichino, Giuseppe, et al.
Publicado: (2022)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
por: Liberini, Virginia, et al.
Publicado: (2020)

Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms
por: Que, Qing-Yang, et al.
Publicado: (2022)

Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
por: Kipnis, Sarit T., et al.
Publicado: (2021)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification
por: Xu, Jun-Xi, et al.
Publicado: (2021)

Cardiac and pericardial tumors: A potential application of positron emission tomography-magnetic resonance imaging
por: Fathala, Ahmed, et al.
Publicado: (2017)

Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors
por: Gallicchio, Rosj, et al.
Publicado: (2023)

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
por: Prétot, Dominique, et al.
Publicado: (2023)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms
por: Canakis, Andrew, et al.
Publicado: (2022)

Quantitative Assessment of Radionuclide Uptake and Positron Emission Tomography-computed Tomography Image Contrast
por: Francis, Hasford, et al.
Publicado: (2016)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
por: Ohlendorf, Fiona, et al.
Publicado: (2021)

Current update on imaging for pancreatic neuroendocrine neoplasms
por: Segaran, Nicole, et al.
Publicado: (2021)

Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma
por: Poels, Thomas T., et al.
Publicado: (2021)

Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance
por: Gallo, Camilla, et al.
Publicado: (2022)

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Alexandraki, Krystallenia I., et al.
Publicado: (2017)

Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
por: Vogele, Daniel, et al.
Publicado: (2023)

Bioremediation: a genuine technology to remediate radionuclides from the environment
por: Prakash, Dhan, et al.
Publicado: (2013)

Microbial interaction with and tolerance of radionuclides: underlying mechanisms and biotechnological applications
por: Lopez‐Fernandez, Margarita, et al.
Publicado: (2020)

Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography in a patient with known metastatic neuroendocrine tumor
por: Schmidt, Matthew Q, et al.
Publicado: (2019)

Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
por: Failla, Mariacristina, et al.
Publicado: (2023)

Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
por: Aristizabal Prada, E T, et al.
Publicado: (2017)

Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives
por: Merola, Elettra, et al.
Publicado: (2022)

Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
por: Binderup, Tina, et al.
Publicado: (2013)

The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience
por: Mohamed, Amr, et al.
Publicado: (2023)

When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer
por: Caldarella, Carmelo, et al.
Publicado: (2013)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
por: Crabtree, Judy S.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4daplmb5apiliffhffa809pa81